Dare Bioscience, Inc. 8-K

What Happened Daré Bioscience, Inc. (DARE) filed a Form 8-K (Item 3.02) reporting that on April 10, 2026 it closed a previously announced Regulation A offering. The company issued 3,470 Investor Units, each unit consisting of one share of Series A Convertible Preferred Stock and two warrants to purchase common stock, at an offering price of $5.00 per Investor Unit.

Key Details

• Offering type: Regulation A offering under Form 1-A (File No. 024-12688), qualified by the SEC April 1, 2026.
• Units issued: 3,470 Investor Units, representing 3,470 shares of Series A Convertible Preferred Stock.
• Warrants issued: Investor Warrants to purchase up to 6,940 shares of common stock (2 warrants per unit).
• Price and proceeds: $5.00 per Investor Unit; aggregate cash raised from this closing = $17,350 (3,470 units × $5).
• Documentation: Offering circular dated January 6, 2026 and offering circular supplement dated March 26, 2026; terms previously disclosed in the company’s January 29, 2026 Form 8-K. 8-K filed April 13, 2026, signed by CEO Sabrina Martucci Johnson.

Why It Matters This filing documents a small Regulation A financing that adds Series A convertible preferred shares and detachable warrants to Daré’s capital structure. While the immediate cash raised from this closing is modest, the Series A preferred shares are convertible and the warrants are exercisable, which could lead to future dilution of common stock if converted or exercised. Investors should review the previously filed offering materials (Form 1-A and the January 29, 2026 8-K) for the conversion and exercise terms to assess potential dilution and timing.